Acura Pharmaceuticals

Executive Summary

Acura Pharmaceuticals is a specialty pharmaceutical company dedicated to developing and commercializing abuse-deterrent formulations of commonly misused medications, particularly opioid painkillers and pseudoephedrine products. The company’s proprietary technology platforms—LIMITX™, AVERSION®, and IMPEDE®—are designed to prevent tampering and misuse via oral overdose, snorting, injection, or conversion into illicit drugs. These technologies aim to preserve therapeutic efficacy while reducing abuse potential, addressing a critical public health need amid the ongoing opioid crisis. Acura maintains both commercial-stage and development-stage products, leveraging its platforms to create differentiated formulations that can be partnered with larger pharmaceutical companies. While Acura Pharmaceuticals is privately held and has not disclosed extensive pipeline details, its strategic focus on abuse-deterrent technologies positions it as a valuable partner for opioid manufacturers seeking to meet regulatory requirements. The company’s AVERSION platform, which incorporates aversive agents to discourage tampering, is among the most prominent in the space. As regulatory agencies push for broader adoption of abuse-deterrent formulations, Acura is well-positioned to license its technologies or co-develop products. However, limited public information and dependence on partnerships introduce execution risk.

Upcoming Catalysts (preview)

• Q3 2026Partnership or licensing deal with a major opioid manufacturer for the AVERSION® or IMPEDE® platform40% success
• Q3 2026FDA acceptance of a new drug application for an abuse-deterrent formulation using LIMITX™ technology20% success
• TBDRelease of positive clinical data from a Phase 2 or Phase 3 trial for a pipeline candidate30% success